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IMPACT OF ATYPICAL AGENTS ON OUTCOMES OF CARE IN
SCHIZOPHRENIC PATIENTS
Joyce AT1, Harrison D2, Ollendorf DA1
1PharMetrics, Watertown, MA, USA; 2Pﬁzer Inc, New York, NY, USA
OBJECTIVE: To compare persistence, compliance, and psychi-
atric treatment costs in patients initiating atypical therapies.
METHODS: Medical and pharmacy claims data were used to
compare persistence (days of therapy between ﬁrst and last pre-
scription, allowing therapy gaps <90 days); compliance (days of
medication supplied with total days on therapy); and treatment
costs in schizophrenic adults with claims for atypicals from
March, 2001 to August, 2003 and enrollment for ≥six-months
before and ≥12 months after therapy initiation. One-year psy-
chiatric treatment costs were examined before and after therapy
initiation. Differences in cost ﬂuctuations were tested by uni-
variate techniques. RESULTS: Persistence was approximately 30
days longer for patients receiving ziprasidone (n = 217; 228 days)
than risperidone (n = 831; 193 days) or olanzapine (n = 762; 201
days). Compliance was signiﬁcantly (P < 0.01) higher among
patients receiving ziprasidone (87%) compared with other treat-
ments (78%–80%). Ziprasidone patients had signiﬁcantly larger
decreases (-$6866) in mean annual psychiatric-related costs fol-
lowing therapy initiation than those on risperidone (-$3353; P
= 0.0116) or olanzapine (-$4764; P = 0.0021). The primary
driver of cost savings was reduced hospitalization after treatment
initiation. CONCLUSION: Patients initiated on ziprasidone had
longer persistence, better compliance, and greater decreases in
psychiatric-related costs than those initiated on other atypicals.
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INCREMENTAL DIRECT COST OF BACK PAIN IN THE UNITED
STATES IN 2001
Balu S,Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: Back pain is an expensive medical condition and
direct medical costs associated with back pain are signiﬁcant.
Estimating resource utilization costs for diseases like back pain
based on disease coding have the potential for under-estimation.
The objective of this study was to determine direct costs due 
to back pain in the US population using an incremental cost
approach. METHODS: Analysis of the 2001 Medical Expendi-
ture Panel Survey (MEPS) was conducted. Patients who had back
pain related physician visits or treatments during 2001 were
identiﬁed using International Classiﬁcation of Diseases (ICD-9)
codes. Patients without a back pain diagnosis and without a
claim for back pain were treated as controls. Least squares
regression was used to estimate the incremental cost of back pain
adjusting for age, gender, race, occupation, and co-morbidities
using the Charlson co-morbidity index. Sample data was pro-
jected to the US population and 95 percent conﬁdence limits for
estimates were calculated using the Taylor expansion method.
RESULTS: Prevalence of back pain in the US was 8.3%
(26,167,199) of the total population. Total annual direct costs
for back pain patients were $32,135,937,092 after adjusting for
co-morbidities. Mean annual direct cost for a back pain patient
was $4241.3 (95% CL $3890.8–$4591.8). Ofﬁce-based medical
provider visits (29.4%), in-patient visits (27.1%), and prescribed
medicines (21.3%) were major cost centers for back pain
patients. CONCLUSIONS: With direct medical costs estimated
at more than $32.0 billion in 2001, back pain costs represent a
signiﬁcant amount of health care expenditures. The estimate
obtained was more than twice the magnitude of earlier estimates
based only on expenditures coded for back pain. Potential for
disease cost under estimation may be reduced by using the incre-
mental cost approach.
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OBJECTIVES: To evaluate the effectiveness of an automated
prior authorization system (SmartPA) in 1) reducing utiliza-
tion/expenditures of Cox-2 inhibitors; 2) increasing utiliza-
tion/expenditures of Cox-2 substitutes (traditional nonsteroidal
anti-inﬂammatory drugs (NSAIDs), other products for pain or
musculoskeletal conditions, and GI protective agents) to no more
than the decrease seen for Cox-2’s; and 3) decreasing Cox-2 uti-
lization/expenditures more in patients at low risk for GI com-
plications than in patients at high risk. METHODS: The study
used a before and after with control group design. Changes in
utilization/expenditures of Cox-2 inhibitors and Cox-2 substi-
tute products were compared after implementation of SmartPA
in Missouri’s Medicaid plan. The Medicaid plan of an eastern
state that had no PA system for Cox-2’s was used as the control.
Subjects were patients with a claim for a Cox-2 inhibitor in the
12-month baseline period that were continuously enrolled for the
24-month study period. Analyses consisted of comparisons of
means and linear regression. Regressions controlled for differ-
ences in age, gender, risk for GI complications, and severity of
illness. RESULTS: Regression results indicated that increases in
expenditures on Cox-2 inhibitors and GI-protective products
were $178 per patient per year (PPPY) higher and $191 PPPY
higher, respectively, in the control state. Increases in expenditures
on traditional NSAIDs and other pain and musculoskeletal prod-
ucts were $34 PPPY higher in the treatment state. Patients at low
risk for GI complications in the treatment state experienced
greater reductions in expenditures than did those in the high-
risk group. Results were similar for utilization for all of the
above analyses. CONCLUSION: SmartPA was successful in
reducing expenditures/utilization on Cox-2 inhibitors for 
Missouri Medicaid compared to the control, while keeping the
increase in expenditures/utilization for Cox-2 substitutes sub-
stantially lower than this decrease. These effects were concen-
trated among patients at low risk for GI complications.
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COMPARISON OF WEIGHT REDUCTION AND SATISFACTION
OF ORLISTAT AND SIBUTRAMINE
Mekaroonreung S,Auamnoy T,Thaweechotepatara P
Chulalongkorn University, Bangkok,Thailand
OBJECTIVE: The objective of this study was to compare and
evaluate the efﬁcacy and satisfaction of orlistat and sibutramine
treatment in obese female patients at adisorn fort hospital in
2004. METHODS: A cross-sectional experimental study by ran-
domized block design was performed. The population was
women age 18 to 45 those whom wanted to reduce their weight
(bmi > 25) with orlistat or sibutramine under physician control
at adisorn fort hospital, Thailand. Sample was calculated by
cohen’s table, setting alpha = 0.05, beta = 0.2, power 0.80 effect
size = 2, sample size (n) = 40. We administered orlistat (360mg/d)
